Q1 2025 TG Therapeutics Inc Earnings Call Transcript
Key Points
- BRIUMVI US net sales reached nearly $120 million in the first quarter, exceeding expectations.
- The company reported a 137% year-over-year growth and 16% sequential quarter-over-quarter growth in BRIUMVI sales.
- Positive real-world experiences and publications support BRIUMVI's efficacy and tolerability, driving patient and prescriber confidence.
- The company is advancing its pipeline with initiatives like a self-administered subcutaneous BRIUMVI and azer-cel, a CD19 CAR-T cell therapy.
- TG Therapeutics Inc (TGTX) increased its full-year 2025 US net revenue guidance for BRIUMVI from $525 million to $560 million.
- Operating expenses, excluding noncash items, were approximately $82 million for the quarter, slightly ahead of full-year guidance.
- The company faces a highly competitive market, particularly from other anti-CD20 therapies.
- Potential tariffs on BRIUMVI, manufactured in South Korea, could impact financial performance, though the company is monitoring the situation.
- The North Carolina manufacturing facility is not expected to produce commercial-scale products for several years.
- The company is not currently focused on profitability, with no specific earnings per share guidance provided.
Greetings and welcome to TG Therapeutics first quarter conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host Jenna Bosco, Chief Communications Officer. Thank you. You may begin.
Thank you. Welcome, everyone, and thanks for joining us this morning. I'm Jenna Bosco, and with me today to discuss the first quarter 2025 financial results are Michael Weiss, our Chairman and Chief Executive Officer; Adam Waldman, our Chief Commercialization Officer; and Sean Power, our Chief Financial Officer.
Following our Safe Harbor Statement, Mike will provide an overview of our recent corporate developments. Adam will share an update on our commercialization efforts and Sean will give a summary of our financial results before turning the call over to the operator to begin the Q&A session.
Before we begin, I'd like to remind everyone that we will be making forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
